MultiCorp International, Inc. Engages BioRegenerative Sciences, Inc. and North County Clinical Research to Develop Clinical Trial Procedures on Patented Migraine Medicine
Procedure Report Will Set Stage to Begin Clinical Trials on Migraine Medication
SUN VALLEY, CA--(Marketwired - Apr 17, 2014) - MultiCorp International, Inc. (PINKSHEETS: MCIC) has engaged Dr. Greg Maguire of BioRegenerative Sciences, Inc., along with Dr. Valentin Isacescu of North County Clinical Research, to work with the company to develop a clear path to begin clinical trials on their patented migraine medicine for eventual approval by the FDA.
The company released the following statement, "We're extremely excited to have such a qualified and experienced group to assist the company in mapping out a clear strategy for the migraine medication to gain approval from the FDA. While we understand this could be a long process, having a group that is so well versed on the proper procedures clinical trials require to gain approval, we feel we've chosen the perfect group to accomplish this portion of the process in the most expeditious manner possible. Once the report is completed in the next four to six weeks, the company will have a clear understanding as to the requirements from the FDA on beginning clinical trials," stated Mr. Paul D. Lisenby, CEO of MultiCorp International, Inc. Mr. Lisenby added, "We feel this medication could become a major player in the $3.2 billion dollar segment of the migraine pharmaceutical vertical."
Dr. Greg Maguire, CEO of BioRegenerative Sciences, Inc., stated, "Our group is very excited to help bring this important new drug candidate for migraines through the FDA 505(b)(2) NDA approval process." Dr Valentin Isacescu added, "Migraine is such a debilitating disorder for so many patients and a tremendous need exists for a medication to prevent and control this malady
